一种将T细胞重编程为类NK细胞的诱导剂及其应用
By using the small molecule compound GSK3735967 as an inducer, T cells were efficiently reprogrammed into NK cell-like cells, solving the problems of low efficiency and high risk in existing technologies, providing a new pathway for the large-scale preparation of NK cell-like cells, and enhancing their anti-tumor function.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- DONGGUAN HENGSHI BIOTECHNOLOGY CO LTD
- Filing Date
- 2026-06-18
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies are insufficient for efficiently reprogramming T cells into NK-like cells, and existing methods suffer from problems such as long cycles, cumbersome processes, low efficiency, high off-target risks, and difficulty in large-scale application.
The small molecule compound GSK3735967 was used as an inducer to promote the differentiation of T cells into NK cells through continuous DNA methyltransferase degradation. Pharmaceutically acceptable excipients were combined to improve the induction efficiency and stability.
This technology enables efficient reprogramming of T cells into NK cell-like cells, improving reprogramming efficiency, reducing off-target and cell damage risks, providing the possibility of standardized production and large-scale preparation of NK cell-like cells, and enhancing anti-tumor function.
Smart Images
Figure CN122405549A_ABST